BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:56 PM
 | 
Feb 02, 2007
 |  BC Extra  |  Clinical News

Humira meets Ph III psoriasis endpoint

In the 1,200-patient Phase III REVEAL trial to treat psoriasis, Abbott's Humira met the two primary endpoints. One primary endpoint was PASI 75 response at week 16,...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >